データなし
データなし
HeartBeam's Arrhythmia Assessment System Gains FDA 510(k) Clearance
HeartBeam Stock Slips 15%
HeartBeam Shares Are Trading Higher After the FDA Granted the Company 510(k) Clearance of Its System for Comprehensive Arrhythmia Assessment.
HeartBeam Announces FDA Clearance for At-Home, High-Fidelity Heart Monitoring Technology
HeartBeam Unveils Data At AHA 2024 For Portable Credit Card-Sized ECG Device; Studies Demonstrate Comparable Arrhythmia Detection To Standard ECGs And Highlight Remote Chest Pain Evaluation To Reduce Heart Attack Care Delays
HeartBeam Announces Positive Data From Two Studies at Prestigious American Heart Association Conference
このコンテンツを閲覧するにはログインが必要です。